EFFECT OF ROSUVASTATIN AND EICOSAPENTAENOIC ACID ON NEOATHEROSCLEROSIS: THE LINK-IT TRIAL

Koji Kuroda,Hiromasa Ohtake,Masakazu Shinohara,Masaru Kuroda,Shigeyasu Tsuda,Takayoshi Toba,Natsuko Tahara,Yuto Shinkura,Kenzo Uzu,Yoshinori Nagasawa,Yuichiro Nagano,Hiroyuki Yamamoto,Kenichi Yanaka,Yoshiro Tsukiyama,Akira Nagasawa,Ryuji Toh,Ishida Tatsuro,Toshiro Shinke,Ken-ichi Hirata

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2018）

引用 11|浏览14

暂无评分

摘要

Neoatherosclerosis is the major cause of late-phase target lesion revascularization (TLR) after stent implantation. We assessed the effect of lipid-lowering therapy with rosuvastatin 10 mg/day and eicosapentaenoic acid (EPA) 1800 mg/day on in-stent neoatherosclerosis using optical coherence

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要